Review top news and interview highlights from the week ending September 22, 2023.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The company is now prioritizing its gene therapy program for Rett syndrome.
The founding president and chief executive officer of Parent Project Muscular Dystrophy discussed recent and upcoming milestones in the field.
Cells from patients with ALL treated in the CARPALL study were analyzed and sequenced.
The chief scientific officer of Precision for Medicine discussed the previous and current delivery methods used for gene therapies and new innovations on the horizon.
The PDUFA data has been set for March 18, 2024.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.